Outlook Therapeutics Raises $10M in Registered Direct Offering
Ticker: OTLK · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $7.00, $7.70 |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-raise, direct-offering, common-stock
Related Tickers: OTLK
TL;DR
OTLK just raised $10M via stock sale, closing around March 15th. Funds for operations.
AI Summary
Outlook Therapeutics, Inc. announced on March 13, 2024, that it entered into a securities purchase agreement for the sale of approximately $10.0 million of its common stock in a registered direct offering. The offering is expected to close on or about March 15, 2024. This capital raise is intended to support the company's ongoing operations and strategic initiatives.
Why It Matters
This capital infusion provides Outlook Therapeutics with crucial funding to continue its operations and advance its strategic goals, potentially impacting its future development and market position.
Risk Assessment
Risk Level: medium — The company is raising capital through a direct offering, which can dilute existing shareholders and may indicate a need for funds to sustain operations.
Key Numbers
- $10.0M — Capital Raised (Through a registered direct offering to fund operations.)
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- $10.0 million (dollar_amount) — Amount raised in securities purchase agreement
- March 13, 2024 (date) — Date of securities purchase agreement
- March 15, 2024 (date) — Expected closing date of the offering
FAQ
What is the purpose of the registered direct offering?
The offering is intended to provide capital to support the company's ongoing operations and strategic initiatives.
When is the expected closing date for this offering?
The offering is expected to close on or about March 15, 2024.
What type of securities were sold in this offering?
The company entered into a securities purchase agreement for the sale of its common stock.
What is the total amount Outlook Therapeutics expects to raise?
Outlook Therapeutics expects to raise approximately $10.0 million.
What is the filing date of this Form 8-K?
This Form 8-K was filed on March 18, 2024, reporting events as of March 13, 2024.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-03-18 17:14:01
Key Financial Figures
- $0.01 — f the Company's common stock, par value $0.01 per share (the "Common Stock"), and, fo
- $7.00 — he "Securities") at a purchase price of $7.00 per Share and accompanying Warrant to p
- $7.70 — The Warrants have an exercise price of $7.70 per share of Common Stock and will expi
Filing Documents
- tm249047d1_8k.htm (8-K) — 26KB
- tm249047d1_ex3-1.htm (EX-3.1) — 8KB
- 0001104659-24-035644.txt ( ) — 210KB
- otlk-20240313.xsd (EX-101.SCH) — 3KB
- otlk-20240313_lab.xml (EX-101.LAB) — 33KB
- otlk-20240313_pre.xml (EX-101.PRE) — 22KB
- tm249047d1_8k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year As previously disclosed, at the 2024 Annual Meeting of Stockholders, the stockholders of the Company approved the amendment of the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock, and a proportionate reduction in the number of authorized shares of Common Stock, at a ratio of 1-for-10 to 1-for-30. Effective March 13, 2024 at 5:00 p.m. Eastern Time, the Company effected a 1-for-20 reverse stock split and proportionate reduction in the number of authorized shares of Common Stock pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") filed with the Secretary of State of the State of Delaware on March 11, 2024. Accordingly, the Company's authorized share capital is 60.0 million shares of Common Stock and there were approximately 13.0 million shares of Common Stock issued and outstanding immediately after effectiveness of the 1-for-20 reverse stock split and proportionate share capital reduction (but prior to eliminating fractions and the issuance of the shares of Common Stock noted in Item 3.02 above). The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment of the Amended and Restated Certificate of Incorporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: March 18, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer